Last reviewed · How we verify
Sarizotan HCl
Sarizotan HCl is a Small molecule drug developed by EMD Serono. It is currently in Phase 2 development.
At a glance
| Generic name | Sarizotan HCl |
|---|---|
| Sponsor | EMD Serono |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia (PHASE3)
- Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sarizotan HCl CI brief — competitive landscape report
- Sarizotan HCl updates RSS · CI watch RSS
- EMD Serono portfolio CI
Frequently asked questions about Sarizotan HCl
What is Sarizotan HCl?
Sarizotan HCl is a Small molecule drug developed by EMD Serono.
Who makes Sarizotan HCl?
Sarizotan HCl is developed by EMD Serono (see full EMD Serono pipeline at /company/emd-serono).
What development phase is Sarizotan HCl in?
Sarizotan HCl is in Phase 2.
Related
- Manufacturer: EMD Serono — full pipeline
- Compare: Sarizotan HCl vs similar drugs
- Pricing: Sarizotan HCl cost, discount & access